Slingshot members are tracking this event:
AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|ABBV||Community voting in process|
Slingshot Insights Explained
Feb 26, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Ema, Orphan Drug Designation, Venetoclax, Aml, Acute Myeloid Leukemia, Myeloblast, Healthy Blood Cells, Chronic Lymphocytic Leukemia